SLC5A2 and diabetic kidney disease: Current treatments of diabetic nephropathy, including sodium‐glucose cotransporter 2 (SGLT‐2) inhibitors and renin‐angiotensin‐aldosterone system (RAAS) inhibitors, delay the progression of diabetic nephropathy and suppress protein O‐GlcNAcylation.